Loading…
← CockpitCompetitor Analysis › 0460.HK Sihuan Pharmaceutical Holdings Group Ltd.Open in the cockpit ↗

Sihuan Pharmaceutical Holdings Group Ltd.0460.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Other
Momentum neutral 43
Mkt cap
$856M
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$2.54M
20-day average traded
Fwd P/E
8.7×
forward earnings
ROIC−WACC
-3.6 pp
WACC 8.4%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · HKDHK$0.73
1D-3.3%
1W-8.7%
1M+2.8%
3M-13.5%
6M-33.8%
YTD-40.2%
1Y-49.7%
ATR %4.1%
52w lowhigh58.9% off high

What Sihuan Pharmaceutical does

Employees: 2,843

Sihuan Pharmaceutical at a glance

Size Sihuan Pharmaceutical (0460.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $856M, the 617th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$0.73 on 18 Nov 2026.

Performance Over six months the shares fell 33.8%, against -18.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 29.7% over the last twelve months (peer median +1.8%); the operating margin is 14.5% (peer median 12.2%).

Valuation It trades at 8.7× forward earnings against a peer median of 21.4× (2nd cheapest of 16).

Capital Return on invested capital runs 3.6 points below its cost of capital (8.4% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 820460.HK 68
Six months, rebased to 100: Sihuan Pharmaceutical against the median of its 20 peers (local-currency closes).

Sihuan Pharmaceutical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$2.94BHK$2.84BHK$2.06BHK$2.06BHK$2.54B
Revenue growth—+38%0%-19%—
Gross profitHK$1.92BHK$1.90BHK$1.27BHK$1.35BHK$1.62B
EBITDAHK$662MHK$658M-HK$175MHK$26.2M-HK$129M
Net incomeHK$341MHK$195M-HK$235M-HK$59.7M-HK$2.27B
Free cash flow-HK$108M-HK$47.3MHK$301MHK$199M-HK$306M
Capital expenditureHK$265MHK$211MHK$202MHK$326MHK$691M
Total debtn/aHK$1.12BHK$1.04BHK$1.40BHK$1.47B

Quarterly statements and history in the cockpit →

Sihuan Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%603262PHN0022192877300791APN0007566004883000390022750025622142300158CRON0775PHMBIOG-B64723015070460.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Sihuan Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×200×400×603262PHN0022192877300791APN0007562142PHM300261BIOG-B64723015070460.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sihuan Pharmaceutical is the large dot.

Sihuan Pharmaceutical competitors and peer comparison

How Sihuan Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sihuan Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure0460.HKPeer medianRank in peer set
1-month return+2.8%-9.2%4th highest of 21
6-month return-33.8%-18.4%4th lowest of 21
Distance from 52-week high-58.9%-39.3%lowest of 21
Revenue growth (TTM)+29.7%+1.8%5th highest of 21
Operating margin14.5%12.2%9th highest of 21
Forward P/E8.7×21.4×2nd cheapest of 16
ROIC minus cost of capital-3.6 pp+1.2 pp5th lowest of 21
EV / EBITDA9.2×18.9×cheapest of 8
Net debt / EBITDA-2.3×-1.1×4th least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%20.0×0.5%+7.9%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%n/an/an/a
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%n/an/an/a
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
ABA Chemicals 300261.SZChina$592M-26%-16%-23%405.0×n/an/a
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%45.4×19.1%+12.1%

Questions

Which companies are Sihuan Pharmaceutical's closest peers?
The cockpit's peer set: TSI (603262.SS), PharmaNutra (PHN.MI), New Journey Health Technology Group Co., Ltd.Class A (002219.SZ), China Shineway Pharmaceutical (2877.HK), Sirio Pharma (300791.SZ), Applied Nutrition (APN.L), Shandong Xinhua Pharmaceutical (000756.SZ), Tianjin Tianyao Pharmaceuticals (600488.SS).
Is Sihuan Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 8.7× against a peer median of 21.4×, 2nd cheapest of 16 in its peer set.
How has Sihuan Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -33.8% against -18.4% for the median peer; over one year -49.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.